Tracers / [90Y]Y-L4-Lipo/
[90Y]Y-L4-Lipo/
Also written as [Y-90]Y-L4-Lipo/
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Lipiodol-based lipophilic ligand formulation (ethyl esters of iodized fatty acids of poppy seed oil complexed with a lipophilic chelating ligand)
- Target / mechanism
- —
- Clinical application
- Transarterial radioembolization (TARE) for selective arterial delivery of localized radiation to advanced unresectable liver tumors, including hepatocellular carcinoma PMID 40493323
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | 95.48 ± 6.72% | 96.25 ± 3.30% | L4-Lipo ligand Guerbet Research and Innovation department, Aulnay-sous-Bois, France | 40493323 2025 EJNMMI Radiopharm Chem A 0.5 mL amount of an [90Y]YCl3 solution was diluted in various 1 M acetate buffers (pH = 3.5, 4.65, 5.2, 7 and 9), purified on Chelex resin, and filtered. — [90Y]Y-L4-Lipo was obtained with a radiochemical yield (RCY) of 95.48 ± 6.72%, as determined by thin-layer chromatography |
Need this precursor?We can point you to suppliers for [90Y]Y-L4-Lipo/, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40493323. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.